IN8bio
Develops gamma-delta T-cell therapies and engagers for cancer and autoimmune disease.
Something off on this page? Send us feedback.
Profile
Develops gamma-delta T-cell therapies and engagers for leukemia, glioblastoma, oncology, and B-cell-driven autoimmune disease. The development-stage company has no approved products or product revenue and depends on clinical progress, regulatory approval, manufacturing partners, licensed intellectual property, and financing.
Develops expanded and genetically engineered gamma-delta T-cell therapies and T-cell engagers through the DeltEx platform. Clinical programs include donor-derived INB-100 after transplant for high-risk leukemia and INB-200, an autologous cell therapy delivered with standard care for newly diagnosed glioblastoma. INB-619 is a preclinical CD19-directed engager for oncology and B-cell-driven autoimmune applications.
Operates from New York with primary research operations in Birmingham and conducts U.S. clinical work through academic centers. Its work centers on gamma-delta T-cell expansion, engineering, and manufacturing, while the company relies on contract manufacturers, licensed university intellectual property, regulatory clearance, and external financing. It has no approved or marketed products and reports a single operating segment.
Company facts
Key statistics
Year to date −57.9% · Average volume (30d) 67.9K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Oct 13, 2025 | Mizuho Securities | Target | $4 | ||
| Feb 11, 2025 | Jones Trading | Upgrade | Hold | Buy |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.34 | −$0.25 | +27.3% | — | — | — | +0.90% |
| May 7, 2026Q1 FY26 | −$0.59 | −$0.26 | +55.9% | — | — | — | −1.25% |
| Mar 12, 2026Q4 FY25 | −$0.18 | −$0.26 | −44.4% | $16.0M | — | — | −1.05% |
| Nov 6, 2025Q3 FY25 | −$1.20 | −$0.85 | +29.2% | — | — | — | −6.63% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$500.0K | $0 | |
| Operating income | −$5.6M | −$5.1M | −$3.9M | −$4.9M | −$5.3M | −$4.8M | |
| Net income | −$5.6M | −$5.1M | −$3.9M | −$4.9M | −$5.1M | −$4.8M | |
| Diluted EPS | −$1.99 | −$1.24 | −$0.85 | −$0.51 | −$0.26 | −$0.25 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $18.0M · Total debt $2.2M · Total assets $21.7M · Shareholders' equity $18.4M
Dividends
No dividends on record.
Ownership
Shares outstanding 9.59M · Float 7.21M · 75.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Lytton Laurence W | 984.0K | 9.99% | 13G | Mar 2, 2026 |
| Alyeska Investment Group, L.P. | 944.3K | 9.85% | 13F | May 15, 2026 |
| Franklin Resources Inc | 914.5K | 9.54% | 13F | May 13, 2026 |
| 683 Capital Management, LLC | 724.6K | 7.56% | 13F | May 15, 2026 |
| Stonepine Capital Management, LLC | 663.4K | 6.92% | 13F | May 14, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Adicet Bio
Allogeneic gamma-delta CAR-T programs overlap in B-cell depletion.
- CytoMed Therapeutics
Donor-derived gamma-delta cell programs overlap in AML and solid tumors.
- Amgen
Approved CD19 T-cell engagement benchmarks the preclinical engager.
- Senti Biosciences
Off-the-shelf CAR-NK therapy contests the AML cell-therapy setting.
- Genmab (ADR)
Subcutaneous CD20 T-cell engagement overlaps in B-cell malignancies.
- Century Therapeutics
Allogeneic CD19 CAR-iT development overlaps with the engager program.
- Immatics
Allogeneic gamma-delta and T-cell-engager platforms overlap in solid tumors.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| IN8bio | $1.04 | +0.82% | $9.9M | — | — | — | — |
| Adicet Bio | $9.06 | +0.17% | $84.7M | — | — | — | — |
| CytoMed Therapeutics | $0.9200 | 0.00% | $10.9M | — | — | 21.6 | +27.0% |
| Amgen | $430.27 | −0.49% | $233.38B | 26.9 | 18.4 | 6.1 | +9.7% |
| Senti Biosciences | $0.3946 | +6.08% | $11.7M | — | — | 213.5 | — |
| Genmab (ADR) | $33.25 | +0.09% | $20.40B | 26.2 | 25.9 | 2.1 | +24.9% |
| Century Therapeutics | $2.03 | +0.25% | $175.3M | — | — | — | — |
| Immatics | $9.35 | −0.95% | $1.27B | — | — | 26.2 | +113.0% |
| Median | 26.5 | 22.1 | 21.6 | +25.9% |